Resource Summary Report

Generated by dkNET on Sep 3, 2026

Calu-1

RRID:CVCL_0608
Type: Cell Line

Proper Citation

RRID:CVCL_0608

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0608

Proper Citation: RRID:CVCL_0608

Description: Cell line Calu-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: PMID:327080, PMID:833871, PMID:3518877, PMID:6582512, PMID:6935474, PMID:7017212, PMID:7459858, PMID:7736387, PMID:7972006, PMID:8385084, PMID:11583962, PMID:12068308, PMID:12794755, PMID:20164919, PMID:20215515, PMID:22460905, PMID:22961666, PMID:24002593, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26361996, PMID:26589293, PMID:28196595, PMID:29681454, PMID:30894373, PMID:31068700, PMID:31978347

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Calu-1

Synonyms: CaLu-1, CALU-1, Calu.1, CALU 1, Calu 1, CALU1, Calu1

Cross References: BTO:BTO_0002940, CLO:CLO_0002191, EFO:EFO_0002151, CLDB:cl631, CLDB:cl632, CLDB:cl633, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-

MTAB-3610, ATCC:HTB-54, BioGRID_ORCS_Cell_line:233, BioSample:SAMN03471732, BioSample:SAMN10988371, cancercelllines:CVCL_0608, CancerTools:161905, CCRID:3101HUMTCHu192, Cell_Model_Passport:SIDM01545, ChEMBL-Cells:CHEMBL3308031, ChEMBL-Targets:CHEMBL613505, CLS:300141, Cosmic:724858, Cosmic:755615, Cosmic:929968, Cosmic:933574, Cosmic:934465, Cosmic:934541, Cosmic:1089224, Cosmic:1146872, Cosmic:1188586, Cosmic:1434968, Cosmic:2060525, Cosmic:2125218, Cosmic:2645023, Cosmic:2646653, Cosmic:2668264, Cosmic:2772160, DepMap:ACH-000511, ECACC:93120818, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:724858, GEO:GSM108801, GEO:GSM108802, GEO:GSM206451, GEO:GSM253387, GEO:GSM274735, GEO:GSM274736, GEO:GSM434324, GEO:GSM784250, GEO:GSM794261, GEO:GSM817063, GEO:GSM843486, GEO:GSM886914, GEO:GSM887980, GEO:GSM1374430, GEO:GSM1374431, GEO:GSM1374432, IARC_TP53:8200, IARC_TP53:21263, ICLC:HTL95002, IGRhCellID:Calu1, IZSLER:BS TCL 76, LiGeA:CCLE_612, LINCS_HMS:50009, LINCS_LDP:LCL-1580, PharmacoDB:Calu1_178_2019, PRIDE:PXD002556, Progenetix:CVCL_0608, PubChem_Cell_line:CVCL_0608, Wikidata:Q54808423

ID: CVCL_0608

Record Creation Time: 20220427T215439+0000

Record Last Update: 20260829T231746+0000

Ratings and Alerts

No rating or validation information has been found for Calu-1.

No alerts have been found for Calu-1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 212 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Brunner JS, et al. (2026) Aspartate availability drives differential engagement of the malate-aspartate shuttle. Molecular cell, 86(5), 954.

Wang J, et al. (2026) Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING. Signal transduction and targeted therapy, 11(1), 44.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Zhu G, et al. (2026) Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. Cell reports, 45(5), 117338.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene, 45(31), 3244.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular cancer research : MCR, 24(1), 60.

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. Biochemical pharmacology, 243(Pt 2), 117562.

Huart C, et al. (2026) PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines. FEBS open bio, 16(7), 1370.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML. Cell metabolism, 38(6), 1113.

Ren D, et al. (2026) Gasdermin C reprograms metabolism through the CAMKK2-AMPK axis to promote lung adenocarcinoma progression and radioresistance. Cell reports, 45(6), 117427.

Güngör Ö, et al. (2026) Triphenylphosphonium-triazole hybrids as mitochondria-targeted anticancer agents: design, DNA binding, cytotoxicity study, fluorescent apoptosis imaging and molecular docking. RSC advances.

Park VS, et al. (2025) Lipid Composition Alters Ferroptosis Sensitivity. Cancer research, 85(22), 4380.

Bratt AS, et al. (2025) Pharmacologic interrogation of USP28 cellular function in p53 signaling. Cell chemical biology.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer cell.

Metur SP, et al. (2025) Yeast TIA1 coordinates with Npl3 to promote ATG1 translation during starvation. Cell reports, 44(2), 115316.

Guler Kara H, et al. (2025) The G protein-coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. The FEBS journal, 292(14), 3755.

Song X, et al. (2025) Cytosolic cytochrome c represses ferroptosis. Cell metabolism, 37(6), 1326.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research,

31(6), 1069.

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. Cancer research, 85(18), 3518.

Pan K, et al. (2025) ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. The Journal of biological chemistry, 302(2), 111110.